genu
coronaviru
belong
plusstrand
rna
viru
famili
coronavirida
current
contain
speci
classifi
three
group
accord
genet
serolog
relationship
coronavirus
cov
infect
human
multipl
speci
anim
caus
varieti
highli
preval
sever
diseas
exampl
human
coronaviru
hcov
strain
caus
signific
portion
upper
lower
respiratori
tract
infect
human
includ
common
cold
bronchiol
pneumonia
also
implic
otiti
media
exacerb
asthma
diarrhea
myocard
neurolog
diseas
previous
unknown
hcov
sever
acut
respiratori
syndrom
coronaviru
sarscov
close
relat
group
ii
cov
prove
etiolog
agent
global
outbreak
lifethreaten
form
pneumonia
call
sever
acut
respiratori
syndrom
sar
caus
fatal
worldwid
anim
cov
mainli
associ
enter
respiratori
diseas
livestock
domest
anim
virus
highli
contagi
signific
mortal
young
anim
result
consider
econom
loss
worldwid
although
vaccin
develop
avian
infecti
bronchiti
viru
ibv
canin
cov
porcin
transmiss
gastroenter
viru
tgev
help
prevent
seriou
diseas
sever
potenti
problem
remain
vaccin
ibv
partial
success
due
continu
emerg
new
serotyp
recombin
event
field
vaccin
strain
develop
vaccin
felin
infecti
periton
viru
fipv
frustrat
phenomenon
antibodydepend
enhanc
licens
vaccin
specif
drug
avail
prevent
hcov
infect
follow
sar
outbreak
seri
inhibitor
report
helicas
main
proteas
mpro
sarscov
prevent
viral
replic
howev
previou
research
place
emphasi
sarscov
structur
data
avail
confirm
direct
interact
inhibitor
target
modif
compound
common
rna
virus
employ
rnadepend
rna
polymeras
genom
replic
cov
gener
thought
mutat
high
frequenc
although
phenomenon
remain
studi
detail
sar
epidem
china
emerg
sarscov
suggest
interspeci
transmiss
viru
continu
evolv
adapt
human
host
cours
outbreak
onethird
mutat
rate
human
immunodefici
viru
high
degre
similar
genom
sequenc
bovin
cov
recent
sequenc
suggest
earlier
animaltohuman
interspeci
transmiss
sarscov
moreov
high
frequenc
rna
recombin
common
featur
cov
genet
demonstr
repres
virus
cov
group
includ
murin
hepat
viru
mhv
tgev
ibv
instanc
outbreak
caus
variant
strain
ibv
aros
recombin
vaccin
wildtyp
virul
strain
chicken
flock
limit
usag
vaccin
ibv
consequ
concern
whether
current
vaccin
drug
develop
effect
next
wave
attack
alter
sarscov
view
issu
pose
develop
widespectrum
drug
exist
pathogen
cov
reason
attract
prospect
individu
strategi
drug
design
therebi
could
provid
effect
first
line
defens
futur
emerg
covrel
diseas
sar
howev
key
factor
control
host
spectrum
viral
pathogen
highli
variabl
among
cov
instanc
cov
use
differ
host
receptor
cellular
entri
poorli
conserv
structur
protein
antigen
encod
divers
accessori
gene
genom
region
probabl
contribut
pathogen
cov
specif
host
clearli
structur
function
divers
present
signific
obstacl
design
versatil
compound
cov
unless
highli
conserv
target
compar
stabl
evolut
identifi
within
genu
coronaviru
report
discoveri
highli
conserv
region
base
four
crystal
structur
one
homolog
model
mpro
repres
three
genet
cluster
genu
coronaviru
uniform
inhibit
mechan
reveal
structur
mproinhibitor
complex
sarscov
tgev
structureassist
optim
program
yield
compound
fast
vitro
inactiv
multipl
cov
mpro
potent
antivir
activ
extrem
low
cellular
toxic
cellbas
assay
modif
could
rapidli
lead
discoveri
singl
agent
clinic
potenti
exist
possibl
futur
emerg
covassoci
diseas
develop
widespectrum
inhibitor
attract
strategi
covassoci
diseas
howev
entir
depend
avail
conserv
target
within
whole
genu
coronaviru
first
round
target
screen
structur
protein
includ
e
n
protein
exclud
due
consider
variat
among
differ
cov
subsequ
rnadepend
rna
polymeras
rna
helicas
mpro
constitut
attract
potenti
nonstructur
protein
target
consider
howev
structur
data
avail
former
two
protein
increas
difficulti
ration
drug
design
downstream
modif
possibl
drug
lead
pivot
role
play
mpro
control
viral
replic
transcript
extens
process
replicas
polyprotein
togeth
absenc
close
relat
cellular
homologu
identifi
mpro
potenti
import
target
antivir
drug
design
howev
pairwis
blast
primari
sequenc
among
cov
mpro
show
ident
case
sinc
acknowledg
threedimension
structur
close
conserv
primari
sequenc
decid
investig
conserv
among
cov
mpro
structur
mpro
show
compar
high
sequenc
similar
within
cov
group
repres
everi
group
chosen
comparison
structur
mpro
tgev
group
group
sarscov
avail
although
crystal
structur
ibv
group
iii
mpro
current
refin
group
nevertheless
use
experimentbas
model
structur
mhv
mpro
group
ii
unavail
previou
studi
shown
sarscov
relat
group
ii
construct
homolog
model
mhv
mpro
base
structur
sarscov
mpro
superposit
crystal
structur
homolog
model
show
approxim
root
mean
squar
deviat
variabl
region
helic
domain
iii
surfac
loop
substratebind
pocket
locat
cleft
domain
ii
especi
highli
conserv
among
cov
mpro
suggest
possibl
widespectrum
inhibitor
design
target
region
mpro
cov
hypothesi
support
enzym
activ
assay
see
tabl
base
assumpt
substratebind
site
highli
conserv
among
cov
mpro
fluorescencelabel
substrat
dnp
synthes
determin
kinet
paramet
tgev
fipv
mhv
ibv
sarscov
mpro
substrat
sequenc
deriv
residu
sarscov
mpro
ntermin
autoprocess
site
sequenc
avlqsgfrk
ibv
mpro
demonstr
almost
ident
km
sarscov
mpro
interest
observ
four
cov
proteas
show
margin
stronger
bind
affin
substrat
sarscov
mpro
result
support
preliminari
biochem
studi
conserv
substrat
cov
mpro
structur
tgev
sarscov
mpro
previous
determin
complex
substrateanalog
chloromethyl
keton
cmk
inhibitor
cbzvnstlqcmk
sequenc
substrateanalog
deriv
residu
ntermin
autoprocess
site
tgev
mpro
howev
two
protom
sarscov
mpro
exhibit
unexpect
bind
mode
possibl
result
compar
weak
bind
peptidyl
element
deriv
substrat
tgev
mpro
highli
reactiv
electrophil
cmk
would
suggest
nucleophil
attack
might
occur
stabl
noncoval
bound
enzymeinhibitor
complex
form
accordingli
singl
bind
mode
tgev
mpro
complex
taken
account
design
possibl
broadspectrum
inhibitor
basi
structur
model
although
cmk
inhibitor
nonselect
high
chemic
reactiv
suscept
cleavag
gastric
enter
proteinas
could
provid
structur
insight
substratebind
pocket
superposit
structur
model
reveal
proteas
catalyt
dyad
rel
conserv
orient
act
proton
acceptor
cy
undergo
nucleophil
attack
carbonyl
carbon
substrat
wide
accept
increas
inhibitor
potenc
achiev
provid
coval
bond
form
activ
cy
residu
design
compound
resembl
intermedi
substrat
cleavag
michael
acceptor
class
conjug
carbonyl
compound
success
introduc
devis
irrevers
cy
proteas
inhibitor
includ
antirhinoviru
compound
ruprintrivir
formerli
design
highli
reactiv
electrophil
cmk
replac
less
reactiv
ethyl
ester
expect
readili
extend
bulki
subsit
cov
mpro
initi
round
inhibitor
design
focus
subsit
crucial
substrat
recognit
util
strategi
mimick
substrat
side
chain
residu
accommod
correspond
subsit
sinc
backbon
cov
mpro
constitut
area
superimpos
particularli
well
except
small
segment
locat
outer
wall
concentr
variat
side
chain
form
pocket
tgev
mpro
complex
structur
side
chain
also
conserv
mpro
incorpor
backbon
element
constitut
site
absolut
requir
gln
posit
via
two
hydrogen
bond
model
show
lactam
stereochemistri
might
preserv
hydrogen
bond
essenti
recognit
moreov
compar
bulki
lactam
ring
would
creat
addit
van
der
waal
interact
side
chain
well
alkyl
portion
side
chain
involv
form
deep
hydrophob
subsit
accommod
rel
larg
side
chain
leu
tgev
mpro
featur
also
observ
mpro
sever
conserv
substitut
occur
cov
mpro
sarscov
mhv
mpro
ibv
mpro
anoth
minor
differ
observ
sarscov
mhv
mpro
outer
wall
segment
compos
short
residu
compar
less
regular
structur
hcov
tgev
mpro
respect
structur
ibv
mpro
undergo
refin
clear
electron
densiti
observ
correspond
stretch
residu
reason
variat
segment
locat
outer
wall
significantli
affect
hydrophob
deep
subsit
support
evid
wherein
leu
found
posit
substrat
cov
mpro
phe
present
ctermin
autocleavag
site
sarscov
phenyl
use
smaller
substitu
explor
subsit
side
chain
thr
solventexpos
site
expect
toler
wide
rang
function
side
chain
form
hydrophob
subsit
tgev
conserv
cov
mpro
exclud
follow
conserv
substitut
hcov
mpro
sarscov
tertiari
butyloxycarbonyl
introduc
posit
ntermin
protect
group
enter
site
thu
combin
modif
novel
compound
design
see
figur
design
seri
analog
synthes
inhibit
assay
see
protocol
coval
irrevers
inactiv
cov
mpro
michael
acceptor
inhibitor
proce
accord
kinet
mechan
present
scheme
inhibitor
initi
form
revers
complex
proteas
undergo
chemic
step
nucleophil
attack
cy
lead
format
stabl
coval
bond
evalu
seri
timedepend
inhibitor
requir
equilibriumbind
constant
ki
design
k
inactiv
rate
constant
coval
bond
format
k
avoid
measur
preincub
assess
effect
timedepend
inhibitor
sinc
gener
trend
valu
decreas
zero
prolong
preincub
time
would
lead
inappropri
evalu
compound
design
first
round
exhibit
obviou
inhibit
cov
mpro
without
preincub
suggest
poor
ki
abl
solv
resolut
crystal
structur
sarscov
mpro
complex
see
figur
tabl
despit
weak
noncoval
bind
order
enhanc
inhibitori
effect
compound
briefli
compound
bind
shallow
cleft
form
portion
strand
eii
segment
loop
link
domain
ii
iii
atom
michael
acceptor
form
coval
bond
expect
lactam
insert
favor
side
chain
val
solventexpos
howev
failur
properli
accommod
correspond
subsit
attract
attent
might
account
poor
inhibitori
effect
seri
molecul
first
although
phenyl
could
enter
site
rigid
prevent
reorient
insert
site
second
ntermin
protect
group
tertiari
butyloxycarbonyl
insert
subsit
possibl
result
planar
properti
butyloxyamid
group
compound
design
round
list
tabl
base
complex
structur
enter
second
round
optim
focus
recognit
site
subsit
phenyl
group
substitut
flexibl
leu
side
chain
order
enhanc
bind
affin
seri
residu
util
substitu
follow
heterocycl
increas
van
der
waal
contact
residu
flank
either
side
round
modif
two
inhibitor
design
efficaci
deriv
name
identifi
fast
vitro
inactiv
cov
mpro
test
includ
tgev
fipv
repres
group
mhv
repres
group
ii
sarscov
relat
group
ii
ibv
repres
group
iii
preliminari
inhibit
assay
see
figur
inhibitor
sensit
mm
concentr
dithiothreitol
dtt
consist
previou
report
type
compound
subsequ
strict
inhibit
kinet
paramet
determin
list
tabl
determin
kinet
paramet
mpro
underway
inhibitor
show
power
inhibit
fipv
mpro
proteas
high
inactiv
rate
kob
measur
ki
k
prove
difficult
case
kob
util
evalu
inhibit
approxim
pseudo
secondord
rate
constant
k
rapid
inactiv
occur
ki
rang
approxim
k
rang
approxim
ki
rang
approxim
k
rang
approxim
compar
demonstr
potent
inhibit
tgev
fipv
mhv
ibv
mpro
kob
rang
approxim
therefor
solv
crystal
structur
sarscov
tgev
mpro
individu
complex
reveal
common
mechan
inhibit
among
cov
mpro
comparison
molecular
surfac
sarscov
mpro
complex
nativ
enzym
show
certain
residu
constitut
subsit
undergo
larg
conform
chang
inhibitor
bind
see
figur
side
chain
flip
shift
superpos
onto
lactam
like
lid
insert
subsit
might
account
movement
main
chain
residu
toward
site
togeth
main
chain
neighbor
residu
cover
site
like
one
half
gate
opposit
side
protrud
around
hydrophob
site
situat
parallel
side
chain
leu
side
chain
anoth
residu
move
upward
form
hydrogen
bond
backbon
nh
two
residu
constitut
half
gate
togeth
two
halv
serv
gateregul
switch
essenti
role
substrat
inhibitor
recognit
bind
clear
electron
densiti
show
atom
form
standard
coval
bond
vinyl
group
suggest
michael
addit
reaction
atom
move
slightli
approxim
toward
interior
protein
compar
nativ
enzym
michael
acceptor
remain
plane
follow
michael
addit
sinc
stabil
water
molecul
order
water
molecul
donat
long
hydrogen
bond
carboxyl
oxygen
ester
accept
hydrogen
bond
backbon
nh
hydrogen
bond
carboxamid
nitrogen
posit
impli
undergo
nucleophil
attack
approach
cloud
carbonyl
oxygen
occupi
oxyanion
hole
close
backbon
nh
mimick
tetrahedr
oxyanion
intermedi
form
ser
proteas
cleavag
howev
standard
hydrogen
bond
form
ethyl
ester
portion
extend
site
suffici
size
extend
conform
interact
alkyl
portion
van
der
waal
interact
lactam
insert
favor
subsit
form
two
stabl
hydrogen
bond
one
lactam
oxygen
anoth
lactam
nh
water
molecul
bottom
subsit
leu
site
move
subsit
approxim
rel
correspond
carbon
atom
leu
form
angl
approxim
phenyl
complex
insert
deepli
subsit
anoth
notabl
differ
insert
ala
latter
replac
isoxazol
block
ntermin
expect
side
chain
ala
current
posit
readili
enter
subsit
simultan
backbon
nh
ala
donat
hydrogen
bond
carbonyl
oxygen
isoxazol
make
van
der
waal
contact
backbon
residu
varieti
substitut
investig
see
tabl
crystal
structur
sarscov
mpro
complex
see
figur
show
val
could
serv
substitu
slightli
increas
hydrophob
interact
anoth
deriv
benzyl
ester
exhibit
improv
inhibit
could
seen
inhibit
assay
fipv
mhv
mpro
see
tabl
cocryst
structur
sarscov
mpro
indic
bulki
benzyl
group
extend
site
possibl
enhanc
van
der
waal
interact
see
figur
two
molecul
per
asymmetr
unit
cocryst
structur
tgev
mpro
compar
mani
six
molecul
per
asymmetr
unit
nativ
enzym
structur
bind
tgev
mpro
similar
mode
sarscov
mpro
subtl
differ
see
figur
first
nucleophil
addit
reaction
michael
acceptor
remain
plane
sarscov
mpro
complex
structur
instead
flip
interact
backbon
atom
residu
unlik
sarscov
mpro
complex
tgev
mpro
lack
water
molecul
connect
ethyl
ester
side
chain
residu
asn
ala
tgev
mpro
rate
chemic
inactiv
presum
depend
reactiv
vinyl
group
orient
extent
transitionst
intermedi
stabil
proteas
suspect
sarscov
mpro
water
molecul
prevent
michael
acceptor
reorient
accept
proton
imidazol
transit
state
although
intermedi
remain
unveil
could
partial
explain
higher
inactiv
rate
constant
k
tgev
mpro
sarscov
mpro
second
anoth
water
molecul
tgev
mpro
complex
occupi
equival
posit
side
chain
interact
backbon
nh
leu
sarscov
complex
water
molecul
howev
donat
hydrogen
bond
accept
hydrogen
bond
nh
backbon
leu
third
isoxazol
sway
interact
backbon
atom
residu
worth
mention
slight
variat
notabl
affect
ki
bind
mode
remain
sarscov
mpro
despit
high
multipl
singlecycl
infect
condit
display
potent
inhibit
fipv
individu
respect
see
figur
dose
respons
curv
show
abl
penetr
cell
deriv
differ
speci
tissu
access
target
consequ
result
strongli
impli
widespectrum
anticov
lead
compound
howev
notic
small
discrep
data
enzymeinhibit
assay
cellbas
assay
explain
differ
cell
inhibitor
enter
potenti
incongru
depend
mpro
differ
cov
furthermor
exclud
potenti
exist
differ
among
bacteri
express
proteas
enzymeinhibit
assay
subtl
differ
activ
fulli
reveal
sarscovderiv
substrat
use
vitro
assay
substanti
data
particular
evalu
abil
type
compound
prevent
cell
infect
cov
cellular
cytotox
murin
delay
brain
tumor
dbt
cellbas
mhv
plaquereduct
assay
perform
follow
reason
three
import
human
pathogen
sarscov
belong
relat
group
ii
cov
age
mice
success
use
model
increas
sever
sar
elderli
human
mhv
plaquereduct
assay
see
figur
consist
determin
mhv
inhibit
assay
observ
concentr
increas
dbt
cell
could
suffici
protect
moreov
display
inhibit
cell
growth
suggest
extrem
low
cellular
toxic
see
figur
result
demonstr
particularli
promis
lead
compound
develop
evid
suggest
cov
may
complet
least
two
animaltohuman
interspeci
transmiss
date
altern
hypothesi
propos
wherebi
pandem
character
malais
fever
pronounc
central
nervou
system
symptom
signific
increas
case
fatal
increas
age
result
interspeci
transmiss
bovin
cov
human
rather
influenza
viru
although
hypothesi
need
evid
support
wide
acknowledg
sar
result
animaltohuman
transmiss
previous
unknown
cov
cov
especi
infect
host
domest
anim
pet
human
frequent
contact
remain
potenti
threat
human
health
assum
cross
interspeci
barrier
henc
develop
widespectrum
drug
lead
increas
protect
human
health
reduct
consider
econom
cost
associ
cov
defens
endang
wild
anim
suscept
infect
valuabl
model
anim
transgen
mice
high
mortal
rate
cov
identif
cov
mpro
conserv
target
among
cov
provid
opportun
develop
broadspectrum
inhibitor
covrel
diseas
ruprintrivir
whose
backbon
also
ester
incorpor
peptidyl
portion
enter
clinic
trial
rhinoviru
infect
although
show
inhibit
cov
compound
poor
aqueou
solubl
low
oral
bioavail
anim
preclin
anim
studi
hydrolysi
compound
produc
alcohol
carboxyl
acid
metabolit
less
activ
ruprintrivir
predomin
biotransform
pathway
ruprintrivir
formul
suspens
intranas
deliveri
phase
ii
studi
report
ruprintrivir
prophylaxi
reduc
proport
subject
posit
viral
cultur
viral
titer
ruprintrivir
well
toler
common
advers
effect
compound
bloodting
mucu
nasal
passag
irrit
highlight
structureassist
optim
could
possibl
lead
discoveri
singl
agent
enter
clinic
trial
covassoci
diseas
although
ultim
clinic
potenti
requir
suffici
investig
latest
result
show
could
also
strongli
inhibit
replic
sarscov
tgev
cellbas
assay
data
publish
elsewher
furthermor
sinc
compound
design
highli
conserv
region
within
genu
coronaviru
effici
resist
high
mutat
recombin
rate
cov
noteworthi
also
exhibit
potent
inhibit
mpro
two
recent
identifi
hcov
associ
bronchiol
conjunct
pneumonia
preliminari
inhibit
assay
see
tabl
strongli
support
hypothesi
singl
agent
develop
could
provid
effect
first
line
defens
futur
emerg
covrel
diseas
moreov
also
suggest
incorpor
michael
acceptor
peptidyl
portion
specif
proteas
would
good
start
point
develop
inhibitor
viral
cy
ser
proteas
comprehens
systemat
program
optim
class
inhibitor
base
cov
mproinhibitor
complex
underway
far
crystal
mhv
mpro
crystal
mpro
recent
identifi
progress
prepar
sarscov
mpro
structur
analysi
describ
previous
method
prepar
sarscov
mpro
activ
assay
almost
ident
except
code
sequenc
insert
bamhi
xhoi
site
express
vector
pharmacia
new
york
unit
state
cdna
encod
ibv
mpro
strain
gift
professor
ming
liao
south
china
agricultur
univers
china
cdna
encod
mpro
mhv
strain
gift
professor
guangxia
gao
institut
biophys
chines
academi
scienc
china
cdna
encod
mpro
kindli
provid
professor
kwokyung
yuen
univers
hong
kong
china
code
sequenc
tgev
ibv
mpro
insert
bamhi
xhoi
site
plasmid
subsequ
method
express
purif
carri
sarscov
mpro
chang
bamhi
cleavag
site
sequenc
code
mhv
mpro
ggctcc
code
sequenc
insert
bamhi
xhoi
site
plasmid
express
fipv
mpro
mgml
mpro
mgml
two
amino
acid
delet
ctermin
express
purifi
describ
previous
sarscov
mpro
crystal
previous
report
sarscov
mpro
inhibitor
complex
prepar
follow
first
inhibitor
dissolv
peg
dmso
me
ph
concentr
mm
supersatur
aliquot
solut
ad
drop
crystal
soak
approxim
day
singl
crystal
prepar
lowtemperatur
data
collect
transfer
cryoprotect
solut
contain
peg
me
ph
flash
frozen
stream
ga
k
set
sarscov
complex
data
collect
resolut
use
imag
plate
marresearch
norderstedt
germani
mount
rigaku
xray
gener
sevenoak
unit
kingdom
oper
kv
data
sarscov
mpro
individu
complex
collect
k
inhous
rigaku
rotatinganod
xray
gener
kv
rigaku
imagepl
detector
data
sarscov
complex
collect
k
inhous
rigaku
rotatinganod
xray
gener
fre
kv
rigaku
imagepl
detector
respect
tgev
mpro
cocryst
prepar
tgev
mpro
incub
molar
excess
h
crystal
trial
perform
method
publish
previous
briefli
condit
crystal
growth
hepe
ph
mpd
mm
dtt
dioxan
set
tgev
complex
data
collect
accord
method
sarscov
complex
intens
data
index
integr
scale
program
denzo
scalepack
data
collect
statist
summar
tabl
sinc
refin
ibv
mpro
structur
ongo
method
crystal
structur
determin
publish
elsewher
method
structur
determin
model
build
refin
publish
previous
briefli
sarscov
complex
structur
determin
molecular
replac
nativ
structur
sarscov
mpro
ph
pdb
id
structur
sarscov
mpro
complex
determin
isomorph
sarscov
complex
structur
tgev
structur
determin
molecular
replac
use
singl
monom
nativ
tgev
mpro
structur
pdb
id
crossrot
translat
search
molecular
replac
perform
cn
adjust
model
made
posit
refin
individu
bfactor
refin
water
pick
perform
cn
valid
final
model
perform
procheck
detail
refin
statist
summar
tabl
activ
mpro
measur
continu
kinet
assay
use
ident
fluorogen
substrat
mcaavlqsgfrli
dnp
puriti
gl
biochem
shanghai
ltd
shanghai
china
fluoresc
intens
monitor
fluoroskan
ascent
instrument
thermolabsystem
helsinki
finland
use
wavelength
nm
excit
emiss
respect
experi
perform
buffer
consist
mm
trishcl
ph
mm
edta
without
dtt
kinet
paramet
km
kcat
determin
initi
rate
measur
respect
sarscov
mpro
reaction
initi
ad
proteas
final
concentr
solut
contain
differ
final
concentr
substrat
concentr
mpro
individu
substrat
rang
activ
assay
follow
ibv
mpro
substrat
rang
mpro
substrat
rang
tgev
mpro
substrat
rang
fipv
mpro
substrat
rang
mhv
mpro
substrat
rang
fluoresc
monitor
point
per
initi
rate
calcul
fit
linear
portion
curv
first
min
progress
curv
straight
line
use
program
origin
originlab
corpor
natick
massachusett
unit
state
initi
veloc
convert
enzym
activ
micromol
substrat
cleav
second
kinet
constant
obtain
doublereciproc
plot
compound
potent
inhibit
identifi
preliminari
inhibit
assay
strict
kinet
paramet
determin
timedepend
inhibitor
progress
curv
fit
firstord
exponenti
equat
yield
observ
firstord
inhibit
rate
constant
kob
p
product
fluoresc
v
initi
veloc
time
displac
term
account
fact
emiss
nonzero
start
data
collect
valu
ki
k
calcul
plot
obtain
equat
versu
accord
equat
inhibitor
concentr
substrat
concentr
km
michaelismenten
constant
substrat
k
rate
constant
inactiv
ki
equilibrium
constantpt
experi
ki
k
valu
irrevers
inhibitor
obtain
reaction
initi
addit
individu
mpro
concentr
similar
enzymat
activ
assay
contain
substrat
depend
enzymat
activ
inhibitor
vari
differ
concentr
molar
excess
enzym
case
data
continu
assay
analyz
nonlinear
regress
analysi
program
origin
fast
inactiv
occur
measur
ki
k
prove
difficult
case
kob
use
approxim
pseudo
secondord
rate
constant
evalu
inhibitor
measur
approxim
differ
inhibitor
concentr
error
associ
determin
kob
less
given
valu
murin
dbt
cell
gener
provid
dr
lishan
su
univers
north
carolina
cultur
dulbecco
modifi
eagl
medium
supplement
fetal
bovin
serum
fb
antibiot
dbt
cell
suspend
growth
medium
triplic
well
plate
preincub
appropri
concentr
inhibitor
next
day
medium
aspir
ad
well
titer
pfuwel
incub
h
viru
inoculum
aspir
ml
mediaagar
overlay
appropri
concentr
inhibitor
ad
well
plate
incub
h
stain
neutral
red
visual
plaqu
dbt
cell
suspend
growth
medium
plate
next
day
appropri
concentr
inhibitor
ad
medium
two
day
later
rel
number
surviv
cell
measur
mtt
sigma
st
loui
missouri
unit
state
assay
accord
manufactur
instruct
human
embryon
lung
fibroblast
cell
atcc
manassa
virginia
unit
state
ccl
feli
catu
whole
fetu
macrophag
cell
fcwf
atcc
crl
dbt
cell
cultur
minim
essenti
medium
mem
supplement
mm
hepe
glutamax
nonessenti
amino
acid
fb
antibiot
nearli
confluent
monolay
incub
follow
infect
fcwf
dbt
cell
grown
plate
infect
fipv
strain
respect
multipl
infect
per
cell
min
viru
adsorpt
viru
inoculum
replac
cell
cultur
medium
contain
vari
concentr
absenc
inhibitor
h
postinfect
viru
titer
cell
cultur
supernat
determin
use
standard
procedur
experi
perform
triplic
mean
valu
determin
